Survival Outcomes in Patients with Resectable Gastric Cancer Treated with Total Neoadjuvant Therapy.
Gastric cancer
Gastric cancer survival
Gastroesophageal junction cancer
Neoadjuvant chemoradiation
Neoadjuvant chemotherapy
Total neoadjuvant therapy
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
24 Jul 2024
24 Jul 2024
Historique:
received:
28
05
2024
accepted:
10
07
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
24
7
2024
Statut:
aheadofprint
Résumé
Perioperative chemotherapy has become the standard of care for locally advanced gastric cancer. Total neoadjuvant therapy (TNT), including both chemotherapy and chemoradiation, is utilized in other gastrointestinal malignancies. We determined survival in a contemporary cohort of gastric cancer patients treated with TNT. Using a prospective institutional database, patients diagnosed with cT2-4 or cN+ gastric adenocarcinoma (January 2012 to June 2022) who underwent staging laparoscopy, received TNT, and underwent gastrectomy were identified. Overall survival (OS) and disease-specific survival (DSS) were determined using standard statistical methods. The study included 203 patients. The most common TNT sequence was induction chemotherapy followed by chemoradiation (n = 186 [91.6%]). A total of 195 (96.1%) patients completed planned neoadjuvant treatments. Surgery included total gastrectomy in 108 (53.2%), extended (D1+/D2) lymphadenectomy in 193 (95.1%), and adjacent organ resection in 19 (9.4%) patients. Pathologic complete response (pCR) was achieved in 32 (15.8%) patients. The 5-year OS rate was 65.2% (95% confidence interval [CI] 57.8-73.5%), and the 5-year DSS rate was 70.8% (95% CI 63.6-78.9%) in the study cohort. Among patients with pCR, the 5-year OS rate was 89.1% (95% CI 78.1-100.0%), and the 5-year DSS rate was 96.9% (95% CI 91-100%). Posttreatment pathologic N and M stages were the strongest prognostic indicators associated with both OS and DSS. Total neoadjuvant therapy for resectable gastric cancer is associated with a high rate of treatment completion and promising survival outcomes. Prospective comparisons with perioperative treatment are needed to identify patients most likely to benefit from TNT.
Sections du résumé
BACKGROUND
BACKGROUND
Perioperative chemotherapy has become the standard of care for locally advanced gastric cancer. Total neoadjuvant therapy (TNT), including both chemotherapy and chemoradiation, is utilized in other gastrointestinal malignancies. We determined survival in a contemporary cohort of gastric cancer patients treated with TNT.
METHODS
METHODS
Using a prospective institutional database, patients diagnosed with cT2-4 or cN+ gastric adenocarcinoma (January 2012 to June 2022) who underwent staging laparoscopy, received TNT, and underwent gastrectomy were identified. Overall survival (OS) and disease-specific survival (DSS) were determined using standard statistical methods.
RESULTS
RESULTS
The study included 203 patients. The most common TNT sequence was induction chemotherapy followed by chemoradiation (n = 186 [91.6%]). A total of 195 (96.1%) patients completed planned neoadjuvant treatments. Surgery included total gastrectomy in 108 (53.2%), extended (D1+/D2) lymphadenectomy in 193 (95.1%), and adjacent organ resection in 19 (9.4%) patients. Pathologic complete response (pCR) was achieved in 32 (15.8%) patients. The 5-year OS rate was 65.2% (95% confidence interval [CI] 57.8-73.5%), and the 5-year DSS rate was 70.8% (95% CI 63.6-78.9%) in the study cohort. Among patients with pCR, the 5-year OS rate was 89.1% (95% CI 78.1-100.0%), and the 5-year DSS rate was 96.9% (95% CI 91-100%). Posttreatment pathologic N and M stages were the strongest prognostic indicators associated with both OS and DSS.
CONCLUSIONS
CONCLUSIONS
Total neoadjuvant therapy for resectable gastric cancer is associated with a high rate of treatment completion and promising survival outcomes. Prospective comparisons with perioperative treatment are needed to identify patients most likely to benefit from TNT.
Identifiants
pubmed: 39048909
doi: 10.1245/s10434-024-15893-7
pii: 10.1245/s10434-024-15893-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Society of Surgical Oncology.
Références
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. https://doi.org/10.3322/caac.21763 .
doi: 10.3322/caac.21763
pubmed: 36633525
Ajani JA, D’Amico TA, Bentrem DJ, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(2):167–92. https://doi.org/10.6004/jnccn.2022.0008 .
doi: 10.6004/jnccn.2022.0008
pubmed: 35130500
Ajani JA, D’Amico TA, Barzi A, et al. NCCN clinical practice guidelines in oncology: GASTRIC CANCer (version 1.2024). Published online March 7, 2024. https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf . Accessed 8 May 2024.
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. https://doi.org/10.1056/NEJMoa055531 .
doi: 10.1056/NEJMoa055531
pubmed: 16822992
Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–57. https://doi.org/10.1016/S0140-6736(18)32557-1 .
doi: 10.1016/S0140-6736(18)32557-1
pubmed: 30982686
In H, Ravetch E, Langdon-Embry M, et al. The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. Gastric Cancer. 2018;21(1):1–9. https://doi.org/10.1007/s10120-017-0765-y .
doi: 10.1007/s10120-017-0765-y
pubmed: 28948368
Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29–42. https://doi.org/10.1016/S1470-2045(20)30555-6 .
doi: 10.1016/S1470-2045(20)30555-6
pubmed: 33301740
Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(5):702–15. https://doi.org/10.1016/S1470-2045(21)00079-6 .
doi: 10.1016/S1470-2045(21)00079-6
pubmed: 33862000
Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40(23):2546–56. https://doi.org/10.1200/JCO.22.00032 .
doi: 10.1200/JCO.22.00032
pubmed: 35483010
pmcid: 9362876
Li SS, Klempner SJ, Costantino CL, et al. Impact of treatment sequencing on survival for patients with locally advanced gastric cancer. Ann Surg Oncol. 2021;28(5):2856–65. https://doi.org/10.1245/s10434-020-09248-1 .
doi: 10.1245/s10434-020-09248-1
pubmed: 33393043
Trimble EL, Ungerleider RS, Abrams JA, et al. Neoadjuvant therapy in cancer treatment. Cancer. 1993;72(S11):3515–24. https://doi.org/10.1002/1097-0142(19931201)72:11+%3c3515::AID-CNCR2820721619%3e3.0.CO;2-A .
doi: 10.1002/1097-0142(19931201)72:11+<3515::AID-CNCR2820721619>3.0.CO;2-A
pubmed: 8242583
Newton AD, Datta J, Loaiza-Bonilla A, Karakousis GC, Roses RE. Neoadjuvant therapy for gastric cancer: current evidence and future directions. J Gastrointest Oncol. 2015;6(5):534–43. https://doi.org/10.3978/j.issn.2078-6891.2015.047 .
doi: 10.3978/j.issn.2078-6891.2015.047
pubmed: 26487948
pmcid: 4570921
Daniel SK, Badgwell BD, McKinley SK, Strong VE, Poultsides GA. Great debate: chemoradiation should be added to chemotherapy as a neoadjuvant treatment strategy for resectable gastric adenocarcinoma. Ann Surg Oncol. 2024;31(1):405–12. https://doi.org/10.1245/s10434-023-14378-3 .
doi: 10.1245/s10434-023-14378-3
pubmed: 37865940
Park SH, Sohn TS, Lee J, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015;33(28):3130–6. https://doi.org/10.1200/JCO.2014.58.3930 .
doi: 10.1200/JCO.2014.58.3930
pubmed: 25559811
Park SH, Lim DH, Sohn TS, et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol. 2021;32(3):368–74. https://doi.org/10.1016/j.annonc.2020.11.017 .
doi: 10.1016/j.annonc.2020.11.017
pubmed: 33278599
Cats A, Jansen EPM, van Grieken NCT, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):616–28. https://doi.org/10.1016/S1470-2045(18)30132-3 .
doi: 10.1016/S1470-2045(18)30132-3
pubmed: 29650363
Leong T, Smithers BM, Michael M, et al. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). BMC Cancer. 2015;15:532. https://doi.org/10.1186/s12885-015-1529-x .
doi: 10.1186/s12885-015-1529-x
pubmed: 26194186
pmcid: 4507314
Slagter AE, Jansen EPM, van Laarhoven HWM, et al. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer. 2018;18(1):877. https://doi.org/10.1186/s12885-018-4770-2 .
doi: 10.1186/s12885-018-4770-2
pubmed: 30200910
pmcid: 6131797
Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22(14):2774–80. https://doi.org/10.1200/JCO.2004.01.015 .
doi: 10.1200/JCO.2004.01.015
pubmed: 15254045
Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005;23(6):1237–44. https://doi.org/10.1200/JCO.2005.01.305 .
doi: 10.1200/JCO.2005.01.305
pubmed: 15718321
Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24(24):3953–8. https://doi.org/10.1200/JCO.2006.06.4840 .
doi: 10.1200/JCO.2006.06.4840
pubmed: 16921048
Badgwell B, Das P, Ajani J. Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy. J Hematol Oncol. 2017;10(1):149. https://doi.org/10.1186/s13045-017-0517-9 .
doi: 10.1186/s13045-017-0517-9
pubmed: 28810883
pmcid: 5558742
National Library of Medicine. Short-course chemoradiotherapy followed by chemotherapy for the treatment of resectable gastric adenocarcinoma. ClinicalTrials.gov. Published January 24, 2024. https://clinicaltrials.gov/study/NCT04523818 . Accessed 31 Dec 2023.
Badgwell BD, Das P, Ikoma N, et al. Phase I trial of short-course chemoradiotherapy followed by chemotherapy as total neoadjuvant therapy for patients with potentially resectable gastric cancer. J Clin Oncol. 2024;42(3_suppl):362–362. https://doi.org/10.1200/JCO.2024.42.3_suppl.362 .
doi: 10.1200/JCO.2024.42.3_suppl.362
Allen CJ, Blumenthaler AN, Smith GL, et al. Chemotherapy versus chemotherapy plus chemoradiation as preoperative therapy for resectable gastric adenocarcinoma: a propensity score-matched analysis of a large, single-institution experience. Ann Surg Oncol. 2021;28(2):758–65. https://doi.org/10.1245/s10434-020-08864-1 .
doi: 10.1245/s10434-020-08864-1
pubmed: 32696305
Allen CJ, Pointer DTJ, Blumenthaler AN, et al. Chemotherapy versus chemotherapy plus chemoradiation as neoadjuvant therapy for resectable gastric adenocarcinoma: a multi-institutional analysis. Ann Surg. 2021;274(4):544. https://doi.org/10.1097/SLA.0000000000005007 .
doi: 10.1097/SLA.0000000000005007
pubmed: 34132693
National Library of Medicine. Nivolumab, ipilimumab and chemoradiation in treating patients with resectable gastric cancer. ClinicalTrials.gov. Published October 12, 2023. https://clinicaltrials.gov/study/NCT03776487 . Accessed 31 Dec 2023.
Agnes A, Estrella JS, Badgwell B. The significance of a nineteenth century definition in the era of genomics: Linitis plastica. World J Surg Oncol. 2017;15(1):123. https://doi.org/10.1186/s12957-017-1187-3 .
doi: 10.1186/s12957-017-1187-3
pubmed: 28679451
pmcid: 5498981
Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med. 1986;5(3):255–60. https://doi.org/10.1002/sim.4780050306 .
doi: 10.1002/sim.4780050306
pubmed: 3738291
R Core Team. R: a language and environment for statistical computing. Published online 2022. https://www.R-project.org .
Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed Intergroup Study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30(19):2327–33. https://doi.org/10.1200/JCO.2011.36.7136 .
doi: 10.1200/JCO.2011.36.7136
pubmed: 22585691
pmcid: 4517071
Vicente D, Ikoma N, Chiang YJ, et al. Preoperative therapy for gastric adenocarcinoma is protective for poor oncologic outcomes in patients with complications after gastrectomy. Ann Surg Oncol. 2018;25(9):2720–30. https://doi.org/10.1245/s10434-018-6638-8 .
doi: 10.1245/s10434-018-6638-8
pubmed: 29987602
Li SS, Udelsman BV, Parikh A, et al. Impact of postoperative complication and completion of multimodality therapy on survival in patients undergoing gastrectomy for advanced gastric cancer. J Am Coll Surg. 2020;230(6):912–24. https://doi.org/10.1016/j.jamcollsurg.2019.12.038 .
doi: 10.1016/j.jamcollsurg.2019.12.038
pubmed: 32035978
Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17(12):1697–708. https://doi.org/10.1016/S1470-2045(16)30531-9 .
doi: 10.1016/S1470-2045(16)30531-9
pubmed: 27776843
Wo JY, Clark JW, Eyler CE, et al. Results and molecular correlates from a pilot study of neoadjuvant induction FOLFIRINOX followed by chemoradiation and surgery for gastroesophageal Adenocarcinomas. Clin Cancer Res. 2021;27(23):6343–53. https://doi.org/10.1158/1078-0432.CCR-21-0331 .
doi: 10.1158/1078-0432.CCR-21-0331
pubmed: 34330715
Al-Batran SE, Shitara K, Folprecht G, et al. Pembrolizumab plus FLOT vs FLOT as neoadjuvant and adjuvant therapy in locally advanced gastric and gastroesophageal junction cancer: interim analysis of the phase 3 KEYNOTE-585 study. J Clin Oncol. 2024;42(3_suppl):247. https://doi.org/10.1200/JCO.2024.42.3_suppl.247 .
doi: 10.1200/JCO.2024.42.3_suppl.247
Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study. J Clin Oncol. 2024;42(3_suppl):LBA246. https://doi.org/10.1200/JCO.2024.42.3_suppl.LBA246 .
doi: 10.1200/JCO.2024.42.3_suppl.LBA246
Badgwell B, Blum M, Estrella J, et al. Predictors of survival in patients with resectable gastric cancer treated with preoperative chemoradiation therapy and gastrectomy. J Am Coll Surg. 2015;221(1):83–90. https://doi.org/10.1016/j.jamcollsurg.2015.04.004 .
doi: 10.1016/j.jamcollsurg.2015.04.004
pubmed: 26002780
Yang J, Greally M, Strong VE, et al. Perioperative versus total neoadjuvant chemotherapy in gastric cancer. J Gastrointest Oncol. 2023. https://doi.org/10.21037/jgo-23-4 .
doi: 10.21037/jgo-23-4
pubmed: 38196544
pmcid: 10772696
Ikoma N, Das P, Hofstetter W, et al. Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: Analyses of the National Cancer Database 2006–2014 using propensity score matching. Gastric Cancer. 2018;21(6):1004–13. https://doi.org/10.1007/s10120-018-0832-z .
doi: 10.1007/s10120-018-0832-z
pubmed: 29730720
pmcid: 6515902
Badgwell B, Ajani J, Blum M, et al. Postoperative morbidity and mortality rates are not increased for patients with gastric and gastroesophageal cancer who undergo preoperative chemoradiation therapy. Ann Surg Oncol. 2016;23(1):156–62. https://doi.org/10.1245/s10434-015-4643-8 .
doi: 10.1245/s10434-015-4643-8
pubmed: 26059652
An JY, Kim HI, Cheong JH, Hyung WJ, Kim CB, Noh SH. Pathologic and oncologic outcomes in locally advanced gastric cancer with neoadjuvant chemotherapy or chemoradiotherapy. Yonsei Med J. 2013;54(4):888–94. https://doi.org/10.3349/ymj.2013.54.4.888 .
doi: 10.3349/ymj.2013.54.4.888
pubmed: 23709422
pmcid: 3663211
Trumbull DA, Lemini R, Díaz Vico T, et al. Prognostic significance of complete pathologic response obtained with chemotherapy versus chemoradiotherapy in gastric cancer. Ann Surg Oncol. 2021;28(2):766–73. https://doi.org/10.1245/s10434-020-08921-9 .
doi: 10.1245/s10434-020-08921-9
pubmed: 32737698
Kaltenmeier C, Althans A, Mascara M, et al. Pathologic complete response following neoadjuvant therapy for gastric adenocarcinoma: a national cancer database analysis on incidence, predictors, and outcomes. Am Surg. 2021;87(7):1145–54. https://doi.org/10.1177/0003134820972083 .
doi: 10.1177/0003134820972083
pubmed: 33342268
Leong T, Smithers BM, Haustermans K, et al. TOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: Interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol. 2017;24(8):2252–8. https://doi.org/10.1245/s10434-017-5830-6 .
doi: 10.1245/s10434-017-5830-6
pubmed: 28337660
Elimova E, Janjigian YY, Mulcahy M, et al. It is time to stop using epirubicin to treat any patient with gastroesophageal adenocarcinoma. J Clin Oncol. 2017;35(4):475–7. https://doi.org/10.1200/JCO.2016.69.7276 .
doi: 10.1200/JCO.2016.69.7276
pubmed: 28129519